论文部分内容阅读
该文从分析云南药用资源状况及开发现状入手,指出云南医药产业以发展与完善“云药”理论,开拓与整合“云药”体系,造就“云药”知名品牌,提高“云药”科技与市场竞争力,优化与推进“云药”基地建设为发展战略。在种植基地建设上,规划建立13个云药道地原生药材规范化种植基地;在产品上,云药现阶段重点发展领域是心脑血管疾病药、创伤类药、呼吸系统疾病药、肝脏疾病药、抗感染药、抗风湿病药、眼科疾病系列药、皮肤病类;云药研究体系建设以现有的研究机构为核心构建新药GLP、GCP研究基地;云药企业体系的构建包括原药材种植企业群、中间提取物企业群(集团)、独家生产产品企业、民族医药企业群、重复生产品种的企业群;并为配合云药产业基地的建设,实施一系列工程和措施。
This article starts with an analysis of the status and development status of medicinal resources in Yunnan, and points out that the Yunnan pharmaceutical industry develops and improves the theory of “cloud medicine”, develops and integrates the “cloud drug” system, and creates a famous brand of “Yunyao”. Enhance the “cloud drug” technology and market competitiveness, optimize and promote the “cloud drug” base construction as a development strategy. In the construction of planting bases, it is planned to establish 13 standardized planting bases for medicinal raw materials for Yunpiao Road. In terms of products, the key development areas of Yunyao at this stage are cardiovascular and cerebrovascular diseases, trauma medicines, respiratory diseases, and liver diseases. , anti-infective drugs, anti-rheumatic drugs, ophthalmic diseases, dermatology; cloud medicine research system construction to the existing research institutions as the core construction of new drugs GLP, GCP research base; cloud pharmaceutical company system including the original medicinal planting Enterprise groups, middle extracts enterprise groups (groups), exclusive production product enterprises, ethnic medicine enterprise groups, and duplicate production enterprise groups; and in order to cooperate with the construction of Yunyao Pharmaceutical Industrial Base, implement a series of projects and measures.